Influence of the minimum inhibitory concentration of daptomycin on the outcomes of Staphylococcus aureus bacteraemia

AlQahtani, Hajar; Baloch, Saeed; Aleanizy, Fadilah Sfouq; Alqahtani, Fulwah Yahya; Tabb, Deanne

doi:10.1016/j.jgar.2020.11.015

Cited by 7 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bacteremia is perhaps the best-described manifestation of S. aureus infection to date. Staphylococcus aureus bacteremia (SAB), caused by S. aureus, the second-most isolated pathogen in the hospital inpatient setting, requires complex medical management, resulting in substantial healthcare costs [ 89 , 90 ]. Most nosocomial and community-acquired SAB is secondary to MRSA and is associated with a high mortality rate and increased hospital stay [ 91 ].…”

Section: Staphylococcus Aureus Caused Bacteremiamentioning

confidence: 99%

“…Most nosocomial and community-acquired SAB is secondary to MRSA and is associated with a high mortality rate and increased hospital stay [ 91 ]. In the USA, S. aureus caused 13.2% of nosocomial bacteremia between 2011 and 2014 [ 89 , 90 ]. It also affects 10 to 30 people per 100,000 annually in the industrialized world [ 92 ].…”

Section: Staphylococcus Aureus Caused Bacteremiamentioning

confidence: 99%

See 1 more Smart Citation

Staphylococcus aureus Infections and Human Intestinal Microbiota

Liu,

Garrett,

Hong

et al. 2024

Pathogens

View full text Add to dashboard Cite

Staphylococcus aureus (S. aureus) is a common pathogen that can cause many human diseases, such as skin infection, food poisoning, endocarditis, and sepsis. These diseases can be minor infections or life-threatening, requiring complex medical management resulting in substantial healthcare costs. Meanwhile, as the critically ignored “organ,” the intestinal microbiome greatly impacts physiological health, not only in gastrointestinal diseases but also in disorders beyond the gut. However, the correlation between S. aureus infection and intestinal microbial homeostasis is largely unknown. Here, we summarized the recent progress in understanding S. aureus infections and their interactions with the microbiome in the intestine. These summarizations will help us understand the mechanisms behind these infections and crosstalk and the challenges we are facing now, which could contribute to preventing S. aureus infections, effective treatment investigation, and vaccine development.

show abstract

Section: Staphylococcus Aureus Caused Bacteremiamentioning

confidence: 99%

Section: Staphylococcus Aureus Caused Bacteremiamentioning

confidence: 99%

Staphylococcus aureus Infections and Human Intestinal Microbiota

Liu,

Garrett,

Hong

et al. 2024

Pathogens

View full text Add to dashboard Cite

show abstract

“…Daptomycin (DAP) is a cyclic lipopeptide antibiotic developed to manage serious infections caused by gram-positive bacteria, primarily bloodstream infections and infectious endocarditis caused by Staphylococcus aureus . 1…”

Section: Introductionmentioning

confidence: 99%

“…Daptomycin (DAP) is a cyclic lipopeptide antibiotic developed to manage serious infections caused by grampositive bacteria, primarily bloodstream infections and infectious endocarditis caused by Staphylococcus aureus. 1 DAP exhibits concentration-dependent activity and linear pharmacokinetics up to doses of 12 mg/kg once daily, with minimal drug accumulation, high protein binding (90%-93%), and predominant renal excretion (approximately 80%). 2 High protein binding and variable renal clearance make it a plausible candidate for therapeutic drug monitoring to optimize achieving pharmacokinetic/ pharmacodynamic (PK/PD) targets.…”

Section: Introductionmentioning

confidence: 99%

Daptomycin Exposure Prediction With a Limited Sampling Strategy

De Gregori,

Seminari,

Capone

et al. 2024

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

Background: Daptomycin is a cyclic lipopeptide antibiotic used to treat serious infectious endocarditis caused by Staphylococcus aureus. The pharmacodynamic parameter correlating best with efficacy is the ratio of the estimated area under the concentration (AUC0-24)–time curve to the minimum inhibitory concentration. The aim of the study is to develop a limited sampling strategy to estimate AUC0-24 using a reduced number of samples. Methods: Sixty-eight daptomycin AUC0-24 values were calculated for 50 White patients who underwent treatment for at least 5 consecutive days. Plasma concentrations were detected using a validated high-performance liquid chromatography–tandem mass spectrometry analytical method, with daptomycin-d5 as an internal standard. Multiple regression was used to evaluate the ability of 2 concentration–time points to predict the AUC0-24 calculated from the entire pharmacokinetic profile. Prediction bias was calculated as the mean prediction error, whereas prediction precision was estimated as the mean absolute prediction error. The development and validation datasets comprised 40 and 10 randomly selected patients, respectively. Results: The AUC0-24 (mg*h/L) was best estimated using the daptomycin trough concentration and plasma concentrations detected 2 hours after dosing. We calculated a mean prediction error of 1.6 (95% confidence interval, −10.7 to 10.9) and a mean absolute prediction error of 11.8 (95% confidence interval, 5.3–18.3), with 73% of prediction errors within ±15%. Conclusions: An equation was developed to estimate daptomycin exposure (AUC0-24), offering clinical applicability and utility in generating personalized dosing regimens, especially for individuals at high risk of treatment failure or delayed response.

show abstract

“…What is more, a large portion of S. aureus infections are difficult to treat because they are caused by methicillin-resistant S. aureus (MRSA) [7], whereas, methicillin is a first line of treatment for S. aureus infections [7]. For MRSA infections, vancomycin is often used as the next line of treatment [8], however, vancomycin-resistant S. aureus (aka VRSA) isolates have also emerged in which case daptomycin may be implemented [9].…”

Section: Introductionmentioning

confidence: 99%

Calcium sulfate beads made with antibacterial essential oil-water emulsions exhibit growth inhibition against Staphylococcus aureus in agar pour plates

et al. 2022

View full text Add to dashboard Cite

Calcium sulfate bone void filler beads are fully absorbable in the body, and are often used in complicated orthopedic infection cases to release a relatively high dose of antibiotics locally to the body site over time. However, the antibiotic resistance crisis and/or inability to treat chronic biofilm infections remains to be a formidable and increasing health threat. In this report, we tested the hypothesis that plant essential oils (PEOs) with anti-staphylococcal qualities could inhibit the growth of Staphylococcus aureus (a major etiological agent of periprosthetic joint infection) in agar pour plates when infused in calcium sulfate beads. To begin, we conducted a screen of 57 single plant PEOs for anti-staphylococcal activity via disk diffusions assays. We observed that 55/57 of the PEOs had significant growth inhibitory activity compared to the null hypothesis, and 41/57 PEOs exhibited activity similar-to-or-higher-than a vancomycin minimum inhibitory control. When PEOs were infused in beads, we observed that 17/57 PEOs tested exhibited significant bacterial growth inhibition when encased in S. aureus-seeded agar compared to a null hypothesis of six millimeters (bead size). However, none of the PEO-beads had activity similar to a vancomycin bead control made according to a clinically relevant formula. To the best of our knowledge, this is the first report and screen of PEOs for growth inhibitory activity when infused in lab-made calcium sulfate beads. These data indicate that antibacterial PEOs warrant further investigations, and may be useful in developing new treatment strategies for periprosthetic joint infection.

show abstract

Influence of the minimum inhibitory concentration of daptomycin on the outcomes of Staphylococcus aureus bacteraemia

Cited by 7 publications

References 11 publications

Staphylococcus aureus Infections and Human Intestinal Microbiota

Staphylococcus aureus Infections and Human Intestinal Microbiota

Daptomycin Exposure Prediction With a Limited Sampling Strategy

Calcium sulfate beads made with antibacterial essential oil-water emulsions exhibit growth inhibition against Staphylococcus aureus in agar pour plates

Contact Info

Product

Resources

About